Skip to main content

Table 2 Evaluation of neoadjuvant therapy efficacy

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Index Evaluation Erlotinib arm n = 12, (%) GC arm n = 12, (%) P value
RECIST PR 7/12 (58.33) 3/12 (25.00) 0.18
  SD 2/12 (16.67) 6/12 (50.00)  
  PD* 3/12 (25.00) 2/12 (16.67)  
  NA 0 (0.00) 1/12 (8.33)  
Clinical N2 downstaging   3/12 (25.00) 3/12 (25.00) 1.00
Pathological N2 downstaging   2/12 (16.67) 3/12 (25.00) 0.64
Resection R0 3/6 (50.00) 5/7 (71.43) 0.59
  R1 3/6 (50.00) 2/7 (28.57)  
  1. Values are presented as n (percentage)
  2. GC gemcitabine/carboplatin, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD stable disease, PD progressive disease, NA not available
  3. *Two patients with the EGFR L858R mutation and the KRAS mutation or EML4-ALK translocation developed primary resistance to induction erlotinib